icon-folder.gif   Conference Reports for NATAP  
 
  IDWeek
October 3 -7, 2019
San Francisco, CA
Back grey_arrow_rt.gif
 
 
 
PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA
 
 
  Reported by Jules Levin
IDWeek 2019™; October 2-6, 2019; Washington, DC, USA
 
CP. Garris1, S. Heidenreich2 ,E. Arthurs3, K. Cutts4, FA. Spinelli1, H. Collacott2, E. Lowman5, H. Rice6, B. Lebouche7, GN. Chua2, H. Gelhorn4 1ViiV Healthcare, RTP, NC, US;2Evidera, London, UK; 3GlaxoSmithKline, Mississauga, ON, Canada; 4Evidera, Bethesda, MD, US; 5Midland Medical Center, Oakland Park, FL, US; 6Rice Medical Group, Mountain View, CA, US; 7Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
 
from Jules: current adherence issues, food restrictions, side effects were important to patients - to physicians side effects & adherence were issues

1023191

1023192

1023193

1023194

1023195

1023196

1023197